These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25397901)

  • 1. Structure-guided DOT1L probe optimization by label-free ligand displacement.
    Yi JS; Federation AJ; Qi J; Dhe-Paganon S; Hadler M; Xu X; St Pierre R; Varca AC; Wu L; Marineau JJ; Smith WB; Souza A; Chory EJ; Armstrong SA; Bradner JE
    ACS Chem Biol; 2015 Mar; 10(3):667-74. PubMed ID: 25397901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
    Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
    Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
    Gibbons GS; Owens SR; Fearon ER; Nikolovska-Coleska Z
    ACS Chem Biol; 2015 Jan; 10(1):109-14. PubMed ID: 25361163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
    Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
    J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.
    Zhang L; Chen Y; Liu N; Li L; Xiao S; Li X; Chen K; Luo C; Chen S; Chen H
    Bioorg Chem; 2018 Oct; 80():649-654. PubMed ID: 30059890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
    Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
    Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Situ Proteome Profiling and Bioimaging Applications of Small-Molecule Affinity-Based Probes Derived From DOT1L Inhibitors.
    Zhu B; Zhang H; Pan S; Wang C; Ge J; Lee JS; Yao SQ
    Chemistry; 2016 Jun; 22(23):7824-36. PubMed ID: 27115831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.
    Yu W; Chory EJ; Wernimont AK; Tempel W; Scopton A; Federation A; Marineau JJ; Qi J; Barsyte-Lovejoy D; Yi J; Marcellus R; Iacob RE; Engen JR; Griffin C; Aman A; Wienholds E; Li F; Pineda J; Estiu G; Shatseva T; Hajian T; Al-Awar R; Dick JE; Vedadi M; Brown PJ; Arrowsmith CH; Bradner JE; Schapira M
    Nat Commun; 2012; 3():1288. PubMed ID: 23250418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
    Basavapathruni A; Jin L; Daigle SR; Majer CR; Therkelsen CA; Wigle TJ; Kuntz KW; Chesworth R; Pollock RM; Scott MP; Moyer MP; Richon VM; Copeland RA; Olhava EJ
    Chem Biol Drug Des; 2012 Dec; 80(6):971-80. PubMed ID: 22978415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study.
    Raj U; Kumar H; Gupta S; Varadwaj PK
    Asian Pac J Cancer Prev; 2015; 16(9):3817-25. PubMed ID: 25987043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor.
    Chen J; Park HJ
    ACS Chem Biol; 2019 May; 14(5):873-881. PubMed ID: 30951287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
    Anglin JL; Song Y
    J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
    Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
    Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
    Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
    Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
    Bon C; Si Y; Pernak M; Barbachowska M; Levi-Acobas E; Cadet Daniel V; Jallet C; Ruzic D; Djokovic N; Djikić T; Nikolic K; Halby L; Arimondo PB
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays.
    Chen S; Li L; Chen Y; Hu J; Liu J; Liu YC; Liu R; Zhang Y; Meng F; Zhu K; Lu J; Zheng M; Chen K; Zhang J; Jiang H; Yao Z; Luo C
    J Chem Inf Model; 2016 Mar; 56(3):527-34. PubMed ID: 26914852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
    Gibbons GS; Chakraborty A; Grigsby SM; Umeano AC; Liao C; Moukha-Chafiq O; Pathak V; Mathew B; Lee YT; Dou Y; Schürer SC; Reynolds RC; Snowden TS; Nikolovska-Coleska Z
    Eur J Med Chem; 2020 Mar; 189():112023. PubMed ID: 31978781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.
    Wang Y; Li L; Zhang B; Xing J; Chen S; Wan W; Song Y; Jiang H; Jiang H; Luo C; Zheng M
    J Med Chem; 2017 Mar; 60(5):2026-2036. PubMed ID: 28165739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
    Waters NJ; Daigle SR; Rehlaender BN; Basavapathruni A; Campbell CT; Jensen TB; Truitt BF; Olhava EJ; Pollock RM; Stickland KA; Dovletoglou A
    J Control Release; 2015 Dec; 220(Pt B):758-65. PubMed ID: 26385168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.